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ABSTRACT
Background OX40 (CD134) is a costimulatory molecule 
of the tumor necrosis factor receptor superfamily that 
is currently being investigated as a target for cancer 
immunotherapy. However, despite promising results in 
murine tumor models, the clinical efficacy of agonistic αOX40 
antibodies in the treatment of patients with cancer has fallen 
short of the high expectation in earlier- stage trials.
Methods Using lymphocytes from resected tumor, tumor- 
free (TF) tissue and peripheral blood mononuclear cells 
(PBMC) of 96 patients with hepatocellular and colorectal 
cancers, we determined OX40 expression and the in vitro 
T- cell agonistic activity of OX40- targeting compounds. 
RNA- Seq was used to evaluate OX40- mediated 
transcriptional changes in CD4+ and CD8+ human tumor- 
infiltrating lymphocytes (TILs).
Results Here, we show that OX40 was overexpressed on 
tumor- infiltrating CD4+ T cells compared with blood and 
TF tissue- derived T cells. In contrast to a clinical candidate 
αOX40 antibody, treatment with an Fc- engineered αOX40 
antibody (αOX40_v12) with selectively enhanced FcγRIIB 
affinity, stimulated in vitro CD4+ and CD8+ TIL expansion, 
as well as cytokine and chemokine secretions. The activity 
of αOX40_v12 was dependent on FcγRIIB engagement 
and intrinsic CD3/CD28 signals. The transcriptional 
landscape of CD4+ and CD8+ TILs shifted toward a 
prosurvival, inflammatory and chemotactic profile on 
treatment with αOX40_v12.
Conclusions OX40 is overexpressed on CD4+ TILs and 
thus represents a promising target for immunotherapy. 
Targeting OX40 with currently used agonistic antibodies may 
be inefficient due to lack of OX40 multimerization. Thus, Fc 
engineering is a powerful tool in enhancing the agonistic 
activity of αOX40 antibody and may shape the future design 
of antibody- mediated αOX40 immunotherapy.
INTRODUCTION
Checkpoint inhibition has revolution-
ized cancer treatment in the past decade. 
However, only a minority of patients suffering 
from solid tumors like hepatocellular carci-
noma (HCC) and colorectal cancer (CRC) 
show sustained responses on blockade of 
PD1 and CTLA4 pathways.1–4 Therefore, 
additional strategies are required to optimize 
cancer immunotherapy. Agonistic antibodies 
targeting costimulatory receptors, particu-
larly tumor necrosis factor receptor (TNFR) 
superfamily members, may represent an 
additional treatment avenue in boosting anti-
tumor immunity.
TNFR member OX40 (TNFRSF4, CD134) 
is transiently expressed on human T helper 
(Th) cells, regulatory T cells (Tregs) and 
CD8+ T cells on T- cell receptor (TCR) activa-
tion, while CD28- mediated costimulation, as 
well as interleukin (IL)-2 augment and sustain 
TCR- induced OX40 expression.5 6 Accord-
ingly, CD4+ and CD8+ tumor- infiltrating 
lymphocytes (TILs) were shown to upreg-
ulate OX40 on coculture with autologous 
tumor cells.7 Although tumor- infiltrating (TI) 
CD4+ T cells derived from several cancers 
express higher OX40 levels than peripheral T 
cells,8–12 in- depth OX40 expression patterns 
on colorectal and HCC cancer- derived CD4+ 
and CD8+ TILs remain largely unknown.
In response to antigen encounter, OX40 
ligation boosts effector T- cell expansion, 
survival, cytokine secretion and memory 
formation in synergy with CD28 costimula-
tion.6 In contrast, OX40 ligation in Tregs 
leads to reduced suppressive activity13–16 by 
suppressing the ‘master regulator’ Foxp3.17 
Efficient signal transduction requires OX40 
multimerization, which could be achieved by 
Fc engineering an αOX40 monoclonal anti-
body to enhance the affinity for inhibitory 
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receptor FcγRIIB in a reporter cell line assay.18 This is 
in line with previous work on other TNFR members, in 
which FcγRIIB- mediated multimerization drives agonistic 
antibody activity, including αCD40,19 20 αDR521 and 
αCD95.22
Due to its expression patterns as well as distinct roles 
on effector T cells and Tregs, OX40 treatment was used 
in several preclinical mouse models to reinvigorate anti-
tumor immunity. OX40 costimulation in mouse models 
was achieved by treatment with agonistic αOX40 anti-
bodies, OX40L.Ig fusion proteins, OX40 RNA aptamers 
and OX40L- expressing tumor cells, which leads to reduced 
tumor burden.23 24 While some studies point toward a direct 
prosurvival effect on CD8+ TILs or CD4- mediated CD8 
help, other studies emphasize reduced suppressive capac-
ities or depletion of Tregs to be the main driver of OX40 
therapy efficacy in mouse tumor models.5
Due to the promising antitumor effects, OX40 antibody- 
mediated immunotherapy either alone or in combina-
tion with antibodies against other immune checkpoint 
molecules, chemotherapy or radiation is already tested 
in several clinical trials.25 Preliminary results of a phase 
I study (NCT02315066) with clinical αOX40 IgG2 anti-
body (PF-8600) confirmed the antitumor properties of 
OX40 targeting as inflammatory and interferon (IFN)-γ 
gene sets were upregulated in tumors of patients under 
OX40 treatment.26 However, only a minority of patients 
(2/48) showed partial clinical responses.27 Besides, more 
phase I studies have been performed in which agonistic 
αOX40 antibody treatment showed low clinical efficacy in 
advanced solid tumors.28 29
Hence, we wondered whether the reason for the limited 
clinical efficacy was due to (1) low OX40 expression on 
human TILs, (2) minor effects of OX40 costimulation on 
TIL functions and expansion, or (3) suboptimal perfor-
mance of the currently used αOX40 antibodies. There-
fore, we measured OX40 levels on distinct TIL subsets of 
colorectal and HCC tumor tissue, thus demonstrating that 
TI activated T- helper (aTh) and activated regulatory T cell 
(aTreg) do express high OX40 levels. Then, we analyzed 
the agonistic activity of several OX40- targeting compounds, 
including the clinical candidate αOX40 and Fc- engi-
neered αOX40_v12 antibody with selectively enhanced 
FcγRIIB affinity on expansion and activation of TILs by 
transcriptomic analyses, flow cytometry and multiplex 
assay. In contrast to the currently used αOX40 antibody, 
Fc- engineered αOX40_v12 induced CD4+ as well as CD8+ 
TIL expansion, increased proinflammatory cytokine and 
chemokine secretion, and shifted the transcriptional land-
scape toward prosurvival and chemotactic pathways. Thus, 
our study might contribute to shaping next- generation 
OX40 immunotherapy for patients with cancer.
METHODS
Patients
In this study, 96 patients and 4 healthy donors 
were enrolled between August 2016 and May 2020. 
Twenty- seven patients with HCC who were eligible for 
resection (n=26) or liver transplantation (n=1) were 
enrolled. Sixty- nine patients with CRC who were eligible 
for resection of primary colorectal cancer (pCRC) (n=43) 
or liver metastasis (LM- CRC) (n=26) were included in this 
study. Matched fresh tissue samples from tumor tissue and 
surrounding tumor- free (TF) tissue (>2 cm from tumor 
margin) were collected and subsequently, intrahepatic or 
intracolorectal as well as TILs were isolated. Peripheral 
blood was obtained perioperatively. Enrolled patients did 
not receive chemotherapy or immunosuppressive therapy 
at least 4 weeks prior to surgery. Online supplementary 
tables 1 and 2 shows clinical patient characteristics. The 
majority of enrolled patients was from Caucasian origin.
Cell preparation
Tumor as well as surrounding TF tissue were either stored 
in University of Wisconsin (UW) solution at 4°C over-
night or immediately processed on receipt. Single- cell 
suspensions were obtained by enzymatic tissue digestion 
followed by ficoll density centrifugation, as described 
previously.30 Details can be found in the online supple-
mentary Methods.
Ex vivo polyclonal T-cell expansion and activation assay
Isolated total TIL and peripheral blood mononuclear 
cell (PBMC) fractions were either used directly for in 
vitro culture or purified using Magnetic Cell Separation 
(MACS). TILs were positively selected using human CD3 
MicroBeads to obtain CD3+ T cells (Miltenyi Biotec, 
130-050-101). CD25- depleted TIL fractions were obtained 
by negatively selecting CD25− TILs with human CD25 
MicroBeads II (Miltenyi Biotec, 130-092-983). Efficiency 
of MACS separation was set to a minimum of 85% purity 
of CD3+ or CD25− TIL, respectively. TILs were cultured 
in Roswell Park Memorial Institute (RPMI) 1640 solu-
tion supplemented with 10% human AB serum 2 mM 
L‐glutamine (Invitrogen), 50 mM Hepes Buffer (Lonza), 
1% penicillin–streptomycin (Life Technologies), 5 mM 
sodium pyruvate (Gibco) and 1% minimum essential 
medium nonessential amino acids at 37°C in 96- well 
round- bottom plates (5×105 CD45+ cells per well) in the 
presence of either αCD3/CD28 activation Dynabeads 
(cell:bead ratio 100-10:1) or 10–100 ng/mL plate- bound 
αCD3 antibody (clone OKT3, BioLegend, 317326). 
Usually, experiments in the range of 15%–90% baseline 
Ki67 expression on T cells after day 8–10 of culture were 
included, unless mentioned otherwise. For indicated 
experiments, TILs were preincubated with 10 µg/mL 
αFcγRIIB- blocking antibody (ch2B6N279Q,31 kind gift 
of MacroGenics) for 60 min at 37°C. Cells were treated 
with 2–20 µg/mL hexameric human OX40L (Pfizer), 
10 µg/mL soluble human αOX40 IgG1, human isotype 
HA- IgG1, human αOX40 IgG2 (PF-04518600), human 
isotype HA- IgG2 or human αOX40IgG1_v12 (all Pfizer). 
αOX40 IgG2 and isotype IgG2 antibody coupling to 
Dynabeads was performed by using Dynabeads Antibody 
coupling Kit according to the manufacturer’s instructions 
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(14 311D), whereby 6 µg antibody was coupled per 1 mg 
of beads. Subsequently, cells were treated with 100 ng/
mL coupled αOX40IgG2- or IgG2 isotype- coupled beads. 
After 8–10 days, culture supernatants were collected and 
quantified using LegendPlex ‘Human T helper Cytokine 
Panel’ or ‘Human Pro- Inflammatory Chemokine Panel’ 
(BioLegend, 740 722 or 740003). Cells were harvested 
and stained with antibodies as indicated in online supple-
mentary table 3. Before flow cytometric measurements on 
FACS Canto or FACSAria II (BD Biosciences), counting 
beads (Thermo Fisher, 01-1234-42) were added to allow 
ratiometric determination of absolute cell counts.
RNA-SEQ AND BIOINFORMATICAL ANALYSES
CD25+ TILs were positively isolated using human CD25 
MicroBeads II (Miltenyi Biotec, 130-092-983) directly after 
TIL isolation. Selected CD25+ TILs were stained with 5 
µM CellTrace Violet (CTV, Thermo Fisher) according to 
the manufacturer’s instructions. Afterwards, CTV- stained 
CD25+ TILs were cocultured with non- stained CD25− 
TILs for 3–5 days in the presence of αCD3/CD28 activa-
tion beads (ctrl) or additionally 10 µg/mL αOX40_v12. 
Then, Th (CD45+CD3+CD56 CD4+CTV−), CD8+ (CD45 
+CD3+CD56 CD8+CTV−) and CD25+ (CD45 +CD3+CD56 
CD4+CTV+) TILs were sorted into 500 µL RLTplus buffer. 
Experimental details can be retrieved from the online 
supplementary Methods.
STATISTICAL ANALYSES
Differences between two paired groups of data were 
analyzed by Wilcoxon matched test. For more than two 
groups, Kruskal- Wallis test was applied. Correlation anal-
ysis according to Spearman was performed. The statistical 
analysis was performed using GraphPad Prism Software 
V.8.0. For DESeq analysis, a cut- off of p<0.05 and fold 
change (FC) of >0.3 was used (*p<0.05, **p<0.01, ***p 
< 0.001).
RESULTS
OX40 is predominantly expressed on TI aTh and aTreg
In this study, resected tumor and surrounding TF tissue 
as well as PBMC of patients with HCC and LM- CRC were 
included, which showed at least some CD3+ immune 
cell infiltration in tumor tissue or at tumor margin 
(>100 000 TILs/1 g tissue). CD8 and CD4+ T- cell subsets 
were present in all tissues; however, frequencies were 
highly variable between patients (online supplementary 
figure S1A). CD4+ T- cell subsets can be distinguished 
into regulatory and effector subsets according to Foxp3 
and CD45RA expression.32 While Th (Th=CD45RA+/− 
Foxp3−) cells do not express transcription factor Foxp3, 
aTh (aTh=CD45RA- Foxp3low) cells express low levels of 
Foxp3 (figure 1A). The highest Foxp3 expression can 
be observed in aTreg (aTreg=CD45RA- Foxp3high), which 
exerts regulatory functions.32 In all tested tumor types, 
CD4+ TILs contained higher frequencies of aTreg as 
compared with CD4+ lymphocytes from either PBMC or 
TF tissue, while resting (r)Treg constituted only a small 
fraction of CD4+ lymphocytes in tumor, TF tissue and 
blood (online supplementary figure S1B). In order to 
evaluate the potential of targeting OX40 in antitumor 
immunotherapy, OX40 expression was measured ex vivo 
on TILs, TF liver- resident and colon- resident lympho-
cytes, as well as PBMC of patients with LM- CRC and 
HCC. Thereby, tumor- derived CD8 cells displayed higher 
OX40 expression compared with PBMC, while Th, aTh 
and aTreg demonstrated higher OX40 levels than PBMC, 
as well as TF tissue- derived CD4+ T cells (online supple-
mentary figure S1D). Throughout all tumor types, aTh 
and aTreg contained significantly higher numbers of 
OX40- expressing cells than Th and CD8 cells, while no 
apparent differences between tumor types were observed 
(figure 1E).
Taken together, CD4+ TILs derived from HCC and 
LM- CRC tissues expressed increased levels of the costim-
ulatory molecule OX40 compared with blood- and TF- de-
rived T cells with highest expression on TI aTh and aTreg.
OX40 crosslinking is essential for OX40-mediated TIL 
expansion and cytokine secretion
We then investigated the effect of the clinical antibody 
αOX40 (IgG2, PF-04518600), as well as an hexameric 
OX40L on freshly isolated HCC- derived, LM- CRC- 
derived and pCRC- derived TILs in an in vitro model 
(figure 2A). Primary TILs were cultured in the presence 
of αCD3/CD28 activation beads to provide initial TCR 
as well as CD28 signaling, which is required for efficient 
OX40- mediated costimulation.5 After 8–10 days of in 
vitro culture, CD4+ and CD8+ TIL expansions were deter-
mined by ratiometric evaluation of cell numbers by flow 
cytometry (online supplementary figure S2A). On costim-
ulation with the monomeric αOX40 antibody, we failed 
to detect expansion of either CD4+ or CD8+ TILs over 
control TILs stimulated in the presence of αCD3/CD28 
alone (figure 2B). In striking contrast, treatment with 
hexameric OX40L led to significant expansion of CD4+ 
and CD8+ TIL numbers and upregulation of prolifera-
tion marker Ki67 (figure 2B,C and online supplementary 
figure S2B–D). Correlating with OX40 expression data, 
CD4+ TILs proliferated to a higher extent than CD8+ 
TILs in response to OX40L treatment (online supple-
mentary figure 2SC,D). Furthermore, elevated levels of 
proinflammatory cytokines IFN-γ, TNF-α, IL-6 and IL-22 
were secreted by OX40L- treated TILs (online supplemen-
tary figure S2E), whereas IFN-γ and TNF-α levels were not 
affected by αOX40 IgG2 treatment (figure 2D). OX40 
is well known to require receptor trimerization for effi-
cient signal transduction.33 Hence, we wondered whether 
multimerizing αOX40 IgG2 antibody to magnetic beads 
might improve its agonistic activity in our in vitro assay. 
Accordingly, we cultured TILs in the presence of either 
monomeric αOX40 antibody or multimerized antibody, 
as well as the respective isotype antibodies. Stimulation 
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with multimerized αOX40 IgG2 significantly upregulated 
CD4+ TIL expansion and showed tendencies to enhance 
CD8+ TIL proliferation (p=0.13) compared with mono-
meric αOX40 (figure 2F).
Thus, OX40- mediated TIL expansion was dependent 
on efficient OX40 crosslinking.
FcγRIIB engagement drives agonistic activity of Fc-
engineered αOX40 antibody
Receptor trimerization of TNFR members can be 
mediated by antibody binding to inhibitory receptor 
FcγRIIB, as shown for αCD40, αCD95 and αDR5 anti-
bodies.19 21 22 Thus, we wondered if the poor efficacy of 
αOX40 IgG2 in our in vitro assay might be attributed 
to insufficient FcγRIIB engagement and therefore 
investigated if Fc engineering can enhance crosslinking 
capacities of αOX40 antibodies. For this purpose, we 
Fc- engineered a human αOX40 antibody (αOX40_v12) 
that contains an IgG1 Fc region comprising six muta-
tions, which resulted in enhanced binding affinity 
to FcγRIIB18 while sharing an identical paratope with 
clinical candidate αOX40 antibody (figure 3A). We 
then treated TILs with wild- type IgG1 or Fc- engineered 
αOX40_v12 antibody and measured TIL expansion at 
the end of the in vitro culture. Compared with its wild- 
type counterpart, agonistic αOX40_v12 led to signifi-
cantly increased CD4+ and CD8+ TIL proliferation 
Figure 1 OX40 is highly expressed on aTreg and aTh TILs. PBMC, TF and tumor tissue from patients with LM- CRC and HCC 
were collected, enzymatically digested and immediately stained. (A) Representative dot plot depicting Treg gating strategy 
using distinctive CD45RA and Foxp3 expression in CD4+ T cells of one patient with HCC (Th=CD45RA±Foxp3−, aTh=CD45RA- 
Foxp3low, aTreg=CD45RA- Foxp3high). (B) Frequencies of Th, aTh and aTreg within CD4+ TILs. (C) Representative 
plot depicting OX40 levels in aTreg of one patient with pCRC. (D,E) OX40 expression was acquired by flow cytometry 
(CD8=CD45+CD3+CD4−). (D,E) One- way non- parametric Kruskal- Wallis, including Dunn’s post- testing, was performed (pCRC 
n=13, LM- CRC n=9, HCC=9); *p≤0.05, **p≤0.01, ***p≤0.001. aTh, activated T helper; aTreg, activated regulatory T cell; HCC, 
hepatocellular carcinoma; LM- CRC, liver metastasis colorectal cancer; PBMC, peripheral blood mononuclear cell; pCRC, 
primary colorectal cancer; TF, tumor- free; Th, T helper; TIL, tumor- infiltrating lymphocyte.
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(figure 3B,C) pointing toward an important role of 
FcγRIIB engagement in OX40 costimulation.
To study the αOX40_v12- induced proliferative effect 
of different CD4+ subsets, we compared cell numbers of 
Foxp3− and Foxp3hi CD4+ TILs after in vitro culture. In 
the majority of samples, Foxp3− CD4+ TILs, responded to 
a higher degree than Foxp3hi TILs (online supplementary 
figure S3A). To verify the potential of Th TILs to respond 
to OX40 costimulation, we cultured CD25- depleted 
TILs for 8–10 days. We observed a similar expansion of 
CD4+ TILs in the presence or absence of CD25+CD4+ 
Treg TILs on day 8–10, suggesting that CD25−CD4+ Th 
TILs respond to OX40 treatment (online supplementary 
figure S3B).
We then assessed the frequencies of B cells, conven-
tional dendritic cells (cDC), monocytes/macrophages 
and natural killer (NK) cells within the CD45+ immune 
cells (online supplementary figure S4A) and determined 
expression of FcγRIIB on those cell types as well as T cells 
(figure 3C,D and online supplementary figure S4C). 
The majority of B cells and cDC expressed FcγRIIB in 
tumor, TF tissue and PBMC, while monocytes and NK 
cells in tumor as well as TF tissue expressed FcγRIIB to 
a smaller extent (figure 3C,D and online supplementary 
figure S4B,C). Since T cells were almost devoid of any 
FcγRIIB expression (figure 3), we compared the effects 
of αOX40_v12 between the total TIL fraction and CD3- 
purified TILs, which were activated with equal ratios of 
αCD3/28 activation beads. While the total TIL fraction 
showed an increase of CD4+ and CD8+ TIL proliferation 
on αOX40_v12 costimulation, CD3- purified TILs failed to 
do so in the absence of FcγRIIB- expressing non- CD3 TILs 
(figure 3E). Lastly, to verify whether FcγRIIB was the main 
mediator of OX40 crosslinking, we antagonized FcγRIIB 
Figure 2 Multimeric OX40 ligation enhances TIL expansion, and activation. Tumor tissues from patients with LM- CRC and 
HCC were collected; immune cells were isolated and cultured in vitro in the presence of αCD3/CD28 activation beads (ctrl) 
and additionally (B,C,E) 20 µg/mL or (C) 2 µg/mL OX40L or (B,D,E) 10 µg/mL monomeric αOX40 IgG2 or (F) multimeric αOX40 
IgG2 for a period of 8–10 days. (A) Schematic outline of hexameric OX40L, monomeric αOX40 IgG2 antibody and αOX40 IgG2 
antibodies conjugated to magnetic beads. (B,C,F) TIL numbers after in vitro cultures were acquired by flow cytometry and 
normalized to counting beads. (B,C) Relative changes over cell numbers in ctrl are shown (n=11). (D,E) Cytokine levels in culture 
supernatants were acquired by cytokine multiplex assay; (D) n=12, (E) n=15). (F) Cell numbers are depicted as relative to soluble 
and bead- conjugated IgG2 isotypes, respectively (n=9). (B) One- way non- parametric Kruskal- Wallis, including Dunn’s post- 
testing and (C–F) non- parametric Wilcoxon test, was performed. *P≤0.05, **P≤0.01, ***P≤0.001. HCC, hepatocellular carcinoma; 
IFN, interferon; LM- CRC, liver metastasis colorectal cancer; ns, not significant; OX40L, OX40 ligand; pCRC, primary colorectal 
cancer; TIL, tumor- infiltrating lymphocyte; TNF-α, tumor necrosis factor alpha.
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by preincubation with a blocking antibody (humanized 
clone ch2B6N279Q) prior to culture with αOX40_v12. 
Blocking FcγRIIB abrogated the αOX40_v12- mediated 
increase in CD4+ and CD8+ TIL expansion and Ki67 
expression (supplementary figures S3F and S4D,E).
Collectively, our data suggest that treatment with 
Fc- engineered antibody αOX40_v12 induced TIL expan-
sion via FcγRIIB engagement.
OX40 costimulation skews the cytokine and chemokine profile 
of CD3+ TILs
OX40 engagement on murine and human PBMC- derived 
T cells has been shown to stimulate production of several 
cytokines and chemokines, including IFN-γ, IL-4, as well 
as CCL20.5 34 To test the impact of OX40 costimulation on 
the cytokine and chemokine profiles of patient- derived 
TILs, we analyzed transcriptomic data of sorted CD25−
CD4+ TILs, CD25+CD4+ TILs and CD8+ TILs of three 
patients that were cultured in the absence or presence of 
agonistic αOX40_v12 antibody. Prior to in vitro culture, 
CD25+ TILs were purified using MACS and labeled with 
CellTrace Violet to enable identification after cocul-
ture with non- stained CD25− TILs (online supplemen-
tary figure S5A,B). Enrichment of Foxp3hi Treg within 
CD25+CD4+ TILs at the time of sorting was verified by 
RNA and protein level (online supplementary figure 
S5C,D).
Treg- enriched CD25+CD4+ TILs acquired a specific 
cytokine profile on OX40 engagement (figure 4A). 
Thereby, IFNG, GZMB, and IL21R were significantly 
upregulated in CD25+CD4+ TILs, while expression of 
several cytokines (IL21, IL6, IL1B, and IL5) was enhanced 
but did not reach statistical significance (as determined 
by p<0.05 and Log2FC>0.3, figure 4A). In accordance 
with enhanced IFNG expression in CD25+CD4+TILs (as 
well as CD25−CD4+ and CD8+ TILs) on OX40 engage-
ment, IFN-γ protein levels in the culture supernatant were 
highly enriched (figure 4A,B), in line with a recent report 
demonstrating the induction of Th1 cytokines in Tregs 
on OX40 ligation.35 Gene set enrichment analysis (GSEA) 
revealed a significant enrichment of gene sets associated 
with ‘IFN-γ response’ in CD25+CD4+ TILs (figure 4C) and 
to a lower extent in CD25−CD4+ and CD8+ TILs (online 
supplementary figure S6B). Besides, IL21R mRNA was 
significantly upregulated in CD25+CD4+ TILs, while IL-21 
protein levels were elevated in supernatants of OX40- 
treated TIL cultures, although not significantly (p=0.06, 
figure 4D). Furthermore, we detected tendencies for 
Figure 3 Fc- engineered αOX40 antibody triggers OX40 costimulation by facilitating FcγRIIB- mediated crosslinking. (A) 
schematic outline of αOX40 v12 depicting six mutations in the Fc region, resulting in selectively enhanced FcγRIIB affinity. (B–F) 
Tumor tissues from patients with LM- CRC and HCC were collected; immune cells were isolated and either (D) directly stained 
or (B,D,F) cultured in the presence of αCD3/CD28 activation beads (ctrl) and additionally αOX40 antibodies or IgG1 isotype 
for a period of 8–10 days. Parts of the TILs were either (E) purified for CD3+ TILs using Magnetic Cell Separation (MACS) 
or (F) pretreated with αFcγRIIB blocking antibody. (B,E,F) TIL numbers after in vitro culture were acquired by flow cytometry 
and normalized to counting beads. Indicated is the FC relative to ctrl- treated cells (B, n=13; E, n=4; F, n=9). (C) Histogram 
representing FcγRIIB expression on TI B (CD45+ CD14 CD19+), conventional dendritic cells (cDC; CD45+CD3−CD14−BDCA1+), 
monocytes (mono=CD45+CD3 CD14+), natural killer (NK; CD45+CD3 CD56+) and T (CD45+CD56 CD3+) cells. (D) FcγRIIB 
expression on TI B, NK and T cells, as well as monocytes and cDC, was measured (n=27). (B,D) One- way non- parametric 
Kruskal- Wallis, including Dunn’s post- testing and (F) non- parametric Wilcoxon test, was performed. *P≤0.05, **P≤0.01, 
***P≤0.001. FC, fold change; HCC, hepatocellular carcinoma; LM- CRC, liver metastasis colorectal cancer; pCRC, primary 
colorectal cancer; TI, tumor- infiltrating; TIL, tumor- infiltrating lymphocyte.
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higher IL21 mRNA levels in CD25+ and CD25−CD4+ TILs 
(online supplementary figure S6A), pointing towards an 
involvement of OX40 costimulation in follicular helper T 
cell (Tfh) differentiation as previously reported.36 37
Moreover, αOX40 treatment led to an increase in 
secretion of Th2/9 family cytokines, like IL-4 and IL-9 
in culture supernatants after 8–10 days, while in some 
patients, elevated mRNA levels of Th2 cytokines were 
already detected at early stages of in vitro culture in 
CD25+CD4+ TILs (days 3–5; figure 4A,D) in accordance 
with previous reports.5 In contrast, IL-17 secretion was 
suppressed in response to OX40 treatment (figure 4E), 
pointing towards a distinctive role of OX40 stimulation 
in Th polarization. OX40 engagement also elevated gene 
expression of several chemokines, including CXCL10 
(figure 4F) as well as CXCL10 and CXCL9 protein 
levels in the culture supernatants. These IFN-γ-inducible 
chemokines were recently demonstrated to be crucial for 
CD8+ T- cell infiltration in tumors38 39 (figure 4G).
Lastly, OX40 signaling was described to be implicated in 
suppression of Treg functions15 17; however, Foxp3 protein 
remained unchanged, while mRNA levels were upregu-
lated in response to OX40 costimulation in CD25+CD4+ 
TILs (online supplementary figure S7A,B). Furthermore, 
Figure 4 OX40 costimulation reprograms cytokine and chemokine landscape of CD4+ TILs. Tumor tissues from patients with 
LM- CRC and HCC were collected and immune cells were isolated. (A,F,C) CD25+ TILs were positively selected, labeled with 
CellTrace Violet (CTV) and cocultured with non- stained CD25− TILs in the presence of αCD3/CD28 activation beads and 10 
µg/mL αOX40_v12 antibodies for or left untreated (ctrl). CD25+ CTV+ TILs were sorted, and RNA was isolated after 3–5 days 
of in vitro culture. (A,F) Heatmap shows color- coded z- scored transcripts per million fragments mapped. Indicated in bold are 
differentially expressed genes (p<0.05 and log2FC>0.3, n=3). (B,D,E,G) TILs were cultured for 8–10 days in the presence of 
αCD3/CD28 activation beads (ctrl) or additionally with αOX40_v12 (v12). Cytokine and chemokine levels in culture supernatants 
were acquired by multiplex assays (B,D,E, n=25; G, n=23). (C) Gene set enrichment analysis (GSEA) was performed according 
to the Broad Institute with the hallmark ‘IFNG response’; indicated is false discovery rate (FDR). (B,D,E,G) Non- parametric 
Wilcoxon test was performed. *P≤0.05, **P≤0.01, ***P≤0.001. HCC, hepatocellular carcinoma; IFN, interferon; IL, interleukin; LM- 
CRC, liver metastasis colorectal cancer; pCRC, primary colorectal cancer; TIL, tumor- infiltrating lymphocyte; FC, fold change.
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in line with a recent report,35 expression of genes associ-
ated with regulatory functions of Treg, including CTLA4, 
IL10, and TGFB1, were not significantly affected by OX40 
treatment in CD25+CD4+ TIL (online supplementary 
figure S7A), while IL-10 secretion was upregulated in 
response to OX40 costimulation in culture supernatants 
(online supplementary figure S7C).
Taken together, OX40 costimulation altered the immu-
nological profile of CD4+ and, to a lower extent, CD8+ 
TILs by boosting chemokine production as well as Tfh- 
related, Th1- related and Th2- related cytokines.
OX40 shapes the transcriptional landscape of TILs by inducing 
prosurvival and chemotaxis pathways
Transcriptomic analyses of TILs cultured in the absence 
or presence of OX40 costimulation showed a profound 
transcriptional shift particularly in the CD25+CD4+ TILs 
as visualized by principal component analysis (figure 5A). 
Figure 5 OX40 skews TILs toward a prosurvival and inflammatory transcriptional profile. Tumor tissues from patients with liver 
metastasis colorectal cancer and HCC were collected and immune cells were isolated. CD25+ TILs were positively selected, 
labeled with CellTrace Violet (CTV) and cocultured with non- stained CD25− TILs in the presence of αCD3/CD28 activation 
beads and 10 µg/mL αOX40_v12 antibodies or left untreated (ctrl). CD25+CTV+ TILs, CTV−CD4+ TILs and CD8+ TILs were 
sorted and RNA was isolated after 3–5 days of in vitro culture. (A) Principal component analysis was performed. (B) Heatmap 
shows color- coded z- scored transcripts per million fragments mapped. (C,D) Ingenuity pathway analysis (IPA) for DE genes of 
disease and function pathways. Dotted line indicates threshold for p value of 0.05. (D) Activation z- score and corresponding p 
values are shown. CRC, colorectal cancer; HCC, hepatocellular carcinoma; LM- CRC, TIL, tumor- infiltrating lymphocyte.
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A total of 891 differentially expressed (DE) annotated 
genes were detected in αOX40_v12- treated versus non- 
treated CD25+CD4+ TILs (p<0.05 and log2FC>0.3). 
Thereby, 630 genes were upregulated, while 261 genes 
were significantly downregulated in response to OX40 
engagement (figure 5B). In CD25−CD4+ or CD8+ 
TILs, 46 or 50 genes were upregulated, whereas 41 or 
55 genes were significantly downregulated, respectively 
(figure 5B). We used Ingenuity pathway analysis (IPA)’s 
knowledge base to identify over- represented functional 
pathways in OX40- treated TILs using DE genes. Cellular 
movement and immune cell trafficking were identified 
among the top predicted pathways pointing toward an 
involvement of OX40 in chemotaxis in CD25+CD4+ and, 
to a lower extent, also in CD25−CD4+ and CD8+ TILs 
(figure 5C). Furthermore, OX40 costimulation led to 
a downregulation of apoptosis and cell death pathways, 
while prosurvival pathways were highly enriched within 
the DE genes of CD25+CD4+ TILs (figure 5D).
In conclusion, OX40 signaling particularly affected 
the transcriptional landscape of CD25+CD4+ TILs by 
inducing prosurvival and cellular movement pathways.
TCR/CD28-mediated TIL preactivation is crucial for 
responsiveness to OX40 costimulation
Since the observed TIL expansion in response to αOX40_
v12 showed high interpatient variability (figure 3B), we 
tried to identify factors that predicted responsiveness to 
OX40 costimulation. First, we plotted the ex vivo expres-
sion of OX40 on freshly isolated TILs against the respec-
tive ‘proliferative response’ to OX40 costimulation on 
days 8–10 of culture. Proliferative response was measured 
as cell number FC of αOX40_v12- treated TILs over 
non- treated TILs. Surprisingly, there was no correlation 
between ex vivo OX40 expression on either total CD4+ 
or CD4+ Foxp3hi TILs to αOX40_v12- triggered prolif-
erative response in CD4+ TILs (online supplementary 
figure S8A). Nor did ex vivo OX40 expression on CD8 
TILs correlate with CD8+ TIL expansion on αOX40_v12 
treatment after culture (online supplementary figure 
S8A). Next, we investigated the impact of underlying 
CD3/CD28- induced T- cell activation to OX40 responsive-
ness since OX40 signaling has been shown to maintain 
initial CD3/CD28- induced prosurvival and proliferative 
signals in T cells.5 We treated patient TILs with different 
αCD3/CD28 cell:bead ratios to achieve a diverse array of 
baseline in vitro activation levels. Then, we plotted the 
baseline in vitro activation (depicted as Ki67 expression 
in control) against the proliferative TIL response after 
in vitro OX40 treatment. Particularly, CD4+ TILs showed 
a robust correlation between baseline in vitro activation 
and OX40- triggered proliferation (figure 6A). Further-
more, using plate- bound αCD3 antibody, we demon-
strated that CD3 signals alone were sufficient to render 
T cells responsive to OX40 costimulation (online supple-
mentary figure S8B).
Since the baseline activation in our assay is mainly 
derived from αCD3/CD28 activation beads, we evaluated 
the ex vivo Ki67 expression levels in CD3+ TILs immedi-
ately after isolation. In tumor tissue, Ki67 expression levels 
were variable but increased compared with lymphocytes 
in TF tissue in both CD4+ and CD8+ TILs (figure 6B). We 
hypothesized that double expression of Ki67 and OX40 
might be a prerequisite of responsiveness to OX40. In 
fact, OX40 expression was enriched in Ki67+CD4+ and 
Ki67+CD8+ TILs (figure 6C). Accordingly, ex vivo OX40 
and Ki67 expression correlated significantly in CD4+ and 
CD8+ TILs (figure 6D). To analyze whether pretreat-
ments like radiation or chemotherapy might influence 
ex vivo Ki67 expression, patients were grouped according 
to whether or not radiotherapy or chemotherapy was 
received within 12 months prior to resection or transplan-
tation. CD4+ and CD8+ TILs of patients who underwent 
previous pretreatment expressed higher levels of Ki67 
than those of untreated patients (online supplementary 
figure S8C).
Taken together, Ki67 expression served as a predictive 
marker for responsiveness to OX40 costimulation in vitro 
and might be enhanced by previous radiotherapy and/or 
chemotherapy.
DISCUSSION
OX40 costimulation represents a promising target for 
cancer immunotherapy as demonstrated in several 
murine models.5 However, the clinical responses to 
agonistic OX40 immunotherapy observed in clinical 
trials did not meet the expectations that were built by the 
success of αOX40 therapy in murine tumor models. In a 
phase I study (NCT02315066), only 2 out of 45 patients 
developed a partial response.27 Thus, we applied ex vivo 
and in vitro assays with human TILs to determine (1) 
OX40 expression on TIL subsets, (2) the impact of OX40 
costimulation on TIL functions and proliferation, and 
(3) the agonistic activities of a current clinical candidate 
αOX40 antibody, as well as a potential next- generation 
antibody.
In a cohort of 96 patients with HCC and CRC, we first 
demonstrated that OX40 expression was increased on 
tumor- derived, proliferating CD4+ and CD8+ TILs. Partic-
ularly, aTh and aTreg overexpressed OX40 compared 
with their counterparts in surrounding tumor- free tissue 
and blood. Thus, we expanded the previous knowledge 
of OX40 expression on human TILs,9–12 further high-
lighting the role of OX40 as a promising target for selec-
tively targeting TILs.
In accordance with disappointing clinical trial 
results,27–29 the clinical candidate human αOX40 IgG2 
antibody failed to stimulate TIL proliferation or cytokine 
secretion in our in vitro expansion assay, while treatment 
with OX40L resulted in TIL expansion and increased 
secretion of proinflammatory cytokines. The clinical 
αOX40 antibody and OX40L differ with regard to their 
structure: αOX40 antibody is monomeric, whereas 
OX40L is of hexameric shape. Thus, when we mimicked 
a multimeric form by conjugating αOX40 antibodies to 
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magnetic beads, αOX40 antibody treatment successfully 
enhanced TIL expansion.
Physiologically, antibody multimerization is driven by 
FcγRIIB engagement.40 Hence, we treated TILs with an 
Fc- engineered αOX40 human IgG1 antibody, termed 
αOX40_v12, that contains six mutations leading to 
increased affinity to FcγRIIB.18 In contrast to the paratope- 
sharing wild- type counterpart, Fc- engineered αOX40_v12 
potently stimulated TIL proliferation and activation 
in this study. Blocking Fc͏γRIIB (which was abundantly 
expressed on TI myeloid and B cells) by a neutralizing 
antibody abrogated the αOX40_v12- induced effects, 
demonstrating the dependence on FcγRIIB engagement. 
Agonistic human αCD40_v2141-11 antibody is another 
example of an Fc- engineered αTNFR antibody with selec-
tively enhanced affinity to FcγRIIB leading to therapeutic 
efficacy in mouse models.41 Fc- engineered agonistic anti-
bodies with improved affinity to FcγRIIB need to undergo 
rigorous toxicity testing since FcγRIIB- triggered systemic 
immune toxicity contributed to the severe cytokine 
release syndrome during the phase I trial of αCD28 IgG4 
antibody.42 Therefore, fully humanized FcR mouse model 
Figure 6 Ki67 expression predicts TIL responsiveness to OX40 stimulation. Tumor tissues from patients with LM- CRC and 
HCC were collected; immune cells were isolated and (B–D) either immediately stained or (A) cultured in vitro in the presence of 
αCD3/CD28 activation beads (ctrl) with or without αOX40_v12 antibody for a period of 8–10 days. (A) X- axis shows fold change 
in cell numbers of αOX40_v12- treated TILs relative to ctrl- treated TILs after in vitro stimulation. Y- axis represents Ki67 levels in 
ctrl- treated TILs after 8–10 days of in vitro culture (n=24). (B) Flow cytometric evaluation of Ki67 expression in freshly isolated 
lymphocytes (n=19). (C) OX40 expression on freshly isolated TILs was acquired by flow cytometry (n=19). (D) Correlation of 
OX40 and Ki67 expression in freshly isolated TILs (n=19). (A,D) Correlation analysis according to Spearman and (B) one- way 
non- parametric Kruskal- Wallis, including Dunn’s post- testing and (C) non- parametric Wilcoxon test were performed. *P≤0.05, 
***P0.001. HCC, hepatocellular carcinoma; LM- CRC, liver metastasis colorectal cancer; TIL, tumor- infiltrating lymphocyte.
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might support the identification of non- toxic dosing regi-
mens as demonstrated for αCD40 antibodies.43
OX40 costimulation has been implicated regulating a 
wide array of cellular functions ranging from the induc-
tion of Th1 and Th2 family cytokines, to the decrease 
of suppressive capacity in Tregs.17 44 45 We observed high 
expression levels of OX40 on TI Foxp3hi CD45RA- aTreg 
which represent a major contributor of tumor immune 
evasion. Therefore, we used transcriptome analyzes to 
reveal the role of OX40 costimulation on the transcrip-
tional network of CD4+ subsets, as well as CD8+ TILs. 
However, the isolation of aTreg after in vitro culture 
posed an irreconcilable challenge due to αCD3/CD28 
signal- mediated upregulation of CD25 expression on 
Th cells.32 Therefore, we isolated CD25+ TILs ex vivo, 
stained them with a cell tracker dye and cocultured 
them together with non- stained CD25− TILs (including 
FcγRIIB+ accessory cells) in the presence or absence of 
αOX40_v12 antibody. We acknowledge that CD25+ TILs 
are a hetergenous population, that is enriched for Treg 
(60-70%) but also contains Foxp3int aTh and Foxp3− Th 
cells. Nevertheless, we observed a shift in the transcrip-
tional landscape of immune mediators early after OX40 
treatment (days 3–5), represented by increased expres-
sion of Th1/2, as well as Tfh cytokines and proinflamma-
tory chemokines, including CXCL8 and CXCL10 in the 
Treg- enriched CD25+CD4+ TIL fraction and to a lower 
extent in Th and CD8+ TILs. The Tfh cytokine IL-21 has 
been associated with increased survival by contributing 
to the formation of tertiary lymphoid structures,46 while 
CXCL9 and CXCL10 are driver chemokines for Th and 
CD8+ infiltration into tumors.39 47 While a shift toward a 
proinflammatory/Th1- like profile was observed, suppres-
sive signatures, including Foxp3 protein, and TGFB and 
CTLA4 gene expression, remained stable in OX40- treated 
CD25+CD4+ TILs, in line with a recent report.35 Thus, 
we hypothesize that human TI Tregs are shifted toward a 
Th1- like profile but maintain the expression of key regu-
latory molecules on OX40 costimulation, suggesting that 
combination therapies with agonistic αOX40 antibodies 
and TGF-β inhibitors or CTLA-4 blockade might be a 
promising therapeutic option.
Due to high heterogeneity of immunological responses, 
the following question prevails in the immunotherapy 
field: how are responders versus non- responders identi-
fied prior to therapy? Even though the implementation 
of PD1 and CTLA4 checkpoint blockade profoundly 
changed antitumor treatment, the response rates espe-
cially in most solid tumor types are considerably low.3 48 A 
multitude of factors have been identified that contribute 
in distinguishing responders from non- responders, 
including PDL1 expression, tumor mutational load, pres-
ence of additional immune- inhibitory pathways as well 
as T- cell infiltration, yet the predictive accuracy is low.48 
We investigated the predictive potential of αCD3/CD28- 
mediated T- cell activation for responsiveness to OX40 
treatment. We demonstrated that OX40 engagement only 
costimulated preactivated, Ki67- expressing TILs but was 
unable to stimulate TILs that are devoid of underlying 
CD3/CD28 signaling.
Of note, ex vivo Ki67 expression in TILs was highly 
variable but significantly correlated with OX40 expres-
sion suggesting that αOX40 immunotherapy mainly 
targets cells that might be sensitive for OX40 costim-
ulation. When studying the patients’ prior treatment 
regimen, it became clear that a previous chemotherapy 
or radiotherapy significantly correlated with enhanced 
Ki67 expression in TILs. Thus, our data support the 
concept of combining OX40 immunotherapy with 
chemotherapy or radiotherapy to render tumor anti-
gens accessible to immune surveillance and boost T- cell 
priming and activation at the tumor site. Currently, 
several clinical studies are under investigation,49 
including a phase I clinical trial combining αOX40 
antibody with radiation in the treatment of metastatic 
breast cancer (NCT018629000).
The strength of our study is the use of patient- 
derived TILs, but this entails several limitations. First, 
we obtained TILs from surgically resected tumors, 
while only a minority of patients with HCC are eligible 
for resection.50 Thus, the cohort of patients with HCC 
included in this study does not represent the majority of 
patients with HCC. Second, purification of TILs partially 
revokes their access to antigen, which is substituted by 
addition of low amounts of polyclonal αCD3/CD28 
activation beads in our study, thereby altering the TIL 
activation status during the in vitro culture. This may 
contribute to the observation that ex vivo OX40 and ex 
vivo Ki67 (data not shown) do not correlate with in vitro 
OX40- mediated responses. Lastly, considering the low 
expression of OX40 on CD8+ TILs ex vivo, it remains 
unclear if CD8+ TILs responded directly or indirectly 
via CD4+ help to OX40 costimulation, as suggested by 
previous studies.5
Here we demonstrate for the first time that an Fc- engi-
neered agonistic αOX40 antibody reinvigorates CD4+ 
and CD8+ TIL expansions, as well as cytokine and chemo-
kine secretions of human TILs. By comparing conven-
tional wild- type with an Fc- engineered antibody, we show 
that OX40 multimerization plays a key role in efficient 
signal transduction, which is driven by FcγRIIB engage-
ment. OX40 costimulation is thereby dependent on 
CD3/CD28 signals and skews the transcriptional profile 
of TI T cells toward a proinflammatory pattern. Thus, 
this study reveals important insights in the requirements 
and mechanisms of agonistic αOX40 treatment and may 
therefore contribute to harnessing the full potential of 
OX40 cancer immunotherapy.
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